Latest Commercialization News

Mesoblast Limited is set to release its full-year financial results and operational highlights for 2025, spotlighting its FDA-approved cell therapy and expanding global partnerships.

Cambium Bio has updated its placement, raising A$2.17 million to fund late-stage clinical trials for its lead ophthalmology product, Elate Ocular®. The capital raise reflects strong investor interest and strategic backing.

Optiscan Imaging Ltd has launched a fully underwritten $17.75 million entitlement offer to fund clinical trials and regulatory clearances for its medical devices, marking a pivotal step in its transition to a commercial medical device manufacturer.

Invion Limited posted a $8.8 million loss for FY25, marking a 56.5% increase, while advancing clinical trials and securing fresh capital. The biotech faces a going concern warning amid ongoing development and funding challenges.

Ava Group Limited reported solid FY25 results with 5% revenue growth to $31.7 million and a turnaround to positive EBITDA of $2.1 million, underpinned by strong demand for its Aura Ai-X security solutions and a robust $88 million sales pipeline.

Ava Risk Group reported a 5% revenue increase to $31.7 million in FY2025, achieving a significant turnaround to $2.1 million underlying EBITDA. The company expanded its Aura Ai-X technology into new sectors and regions despite some order delays.

Provaris Energy has raised $1 million through a share placement to accelerate its hydrogen and CO2 storage and transport commercialisation programs, targeting new markets in Asia and Europe.

Invictus Energy has forged a landmark partnership with Al Mansour Holdings, securing a strategic 19.9% stake and up to US$500 million in funding to advance its Cabora Bassa Project and expand into African upstream oil and gas markets.

archTIS Limited has reported FY25 results with solid ARR growth and completed a transformative acquisition of Spirion LLC, significantly boosting its US market presence and product suite. The company is raising $20.5 million to fund this expansion and accelerate growth.

Critical Metals Corp has signed a multi-year letter of intent to supply rare earth concentrate from its Greenland project to Ucore Rare Metals’ US Department of Defense-backed processing facility, aiming to build a China-independent supply chain.

Ark Mines Ltd is fast-tracking its Sandy Mitchell rare earths project in Queensland, backed by a $4.5 million investment from the Queensland Investment Corporation and targeting production by late 2027.

Compumedics Limited reported a 2% revenue increase and a 22% jump in sales orders for FY25, driven by strong demand in sleep diagnostics and SaaS platforms, while navigating a net loss impacted by higher financing costs.